All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Reflecting the concerns voiced by nearly three dozen patients in a public hearing, members of the FDA's Antimicrobial Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee voted Thursday to recommend changes in how systemic fluoroquinolone drugs are labeled to treat a trio of non-life-threatening infections.